Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 3
2013 2
2014 3
2021 1
2022 1
2023 2
2024 2
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Antipsychotics and risk of QT prolongation: a pharmacovigilance study.
Bordet C, Garcia P, Salvo F, Touafchia A, Galinier M, Sommet A, Montastruc F. Bordet C, et al. Psychopharmacology (Berl). 2023 Jan;240(1):199-202. doi: 10.1007/s00213-022-06293-4. Epub 2022 Dec 14. Psychopharmacology (Berl). 2023. PMID: 36515735
Lurasidone was associated with the lowest risk. First-generation antipsychotics were associated with a greater QT prolongation reporting risk (ROR, 1.21; 95%CI, 1.10-1.33) than second-generation antipsychotics. ...CONCLUSIONS: This large study in a real-world settin …
Lurasidone was associated with the lowest risk. First-generation antipsychotics were associated with a greater QT prolongation …
Risk Stratification of QTc Prolongation in Critically Ill Patients Receiving Antipsychotics for the Management of Delirium Symptoms.
Sadlonova M, Beach SR, Funk MC, Rosen JH, Ramirez Gamero AF, Karlson RA, Huffman JC, Celano CM. Sadlonova M, et al. J Intensive Care Med. 2025 Apr;40(4):355-371. doi: 10.1177/08850666231222470. Epub 2023 Dec 21. J Intensive Care Med. 2025. PMID: 38130132 Review.
Among other antipsychotics, those most likely to cause QTc prolongation are iloperidone and ziprasidone, while aripiprazole and lurasidone appear to have minimal risk for QTc prolongation. Genetic vulnerabilities, female sex, older age, pre-existing cardiovascular disease, …
Among other antipsychotics, those most likely to cause QTc prolongation are iloperidone and ziprasidone, while aripiprazole and lurasidon …
Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis.
Rogdaki M, McCutcheon RA, D'Ambrosio E, Mancini V, Watson CJ, Fanshawe JB, Carr R, Telesia L, Martini MG, Philip A, Gilbert BJ, Salazar-de-Pablo G, Kyriakopoulos M, Siskind D, Correll CU, Cipriani A, Efthimiou O, Howes OD, Pillinger T. Rogdaki M, et al. Lancet Child Adolesc Health. 2024 Jul;8(7):510-521. doi: 10.1016/S2352-4642(24)00098-1. Lancet Child Adolesc Health. 2024. PMID: 38897716 Free PMC article.
Primary outcomes were mean change from baseline to end of acute treatment in bodyweight, BMI, fasting glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, prolactin, heart rate, systolic blood pressure (SBP), and QT interval corrected for heart rate …
Primary outcomes were mean change from baseline to end of acute treatment in bodyweight, BMI, fasting glucose, total cholesterol, LDL choles …
Management of psychosis and agitation in medical-surgical patients who have or are at risk for prolonged QT interval.
Ries R, Sayadipour A. Ries R, et al. J Psychiatr Pract. 2014 Sep;20(5):338-44. doi: 10.1097/01.pra.0000454778.29433.7c. J Psychiatr Pract. 2014. PMID: 25226194 Review.
We review the literature on management of psychosis and agitation in medical-surgical patients who have or are at risk for prolonged QT interval, a risk factor for torsade de pointes (TdP), and we describe our protocols for treating these patients. ...Antipsychotics …
We review the literature on management of psychosis and agitation in medical-surgical patients who have or are at risk for prolonged QT …
Lurasidone : in the treatment of schizophrenia.
Sanford M. Sanford M. CNS Drugs. 2013 Jan;27(1):67-80. doi: 10.1007/s40263-012-0026-x. CNS Drugs. 2013. PMID: 23264146 Review.
In an unpublished trial, there were no significant differences between lurasidone, active comparator and placebo groups on the primary endpoint. Lurasidone was generally well tolerated over the short and longer term. Extrapyramidal symptoms and akathisia occurred in …
In an unpublished trial, there were no significant differences between lurasidone, active comparator and placebo groups on the primar …
Lurasidone: a clinical overview.
Kane JM. Kane JM. J Clin Psychiatry. 2011;72 Suppl 1:24-8. doi: 10.4088/JCP.10075su1.05. J Clin Psychiatry. 2011. PMID: 22217440 Review.
Lurasidone is a new second-generation (atypical) antipsychotic approved for the treatment of schizophrenia in adults. ...Lurasidone is associated with some somnolence, akathisia, nausea, and parkinsonism, especially early in treatment. ...
Lurasidone is a new second-generation (atypical) antipsychotic approved for the treatment of schizophrenia in adults. ...Lurasidon …
Lurasidone in schizophrenia: new information about dosage and place in therapy.
Citrome L. Citrome L. Adv Ther. 2012 Oct;29(10):815-25. doi: 10.1007/s12325-012-0052-6. Epub 2012 Sep 20. Adv Ther. 2012. PMID: 23001538 Review.
The totality of the evidence supports the overall tolerability of lurasidone, with minimal weight gain and no clinically-meaningful alterations in glucose, lipids, or the electrocardiogram corrected QT (ECG QTc) interval. ...Principal advantages over some other seco …
The totality of the evidence supports the overall tolerability of lurasidone, with minimal weight gain and no clinically-meaningful a …
Lurasidone for schizophrenia: what's different?
Kantrowitz JT, Citrome L. Kantrowitz JT, et al. Expert Rev Neurother. 2012 Mar;12(3):265-73. doi: 10.1586/ern.12.7. Expert Rev Neurother. 2012. PMID: 22364325 Review.
Several Phase II and III studies have established that lurasidone is more efficacious than placebo. There are no available adequately powered head-to-head comparisons of efficacy of lurasidone with other antipsychotics. However, in contrast to some other antipsychot …
Several Phase II and III studies have established that lurasidone is more efficacious than placebo. There are no available adequately …
Identification of clinical phenotypes in schizophrenia: the role of lurasidone.
Riva MA, Albert U, de Filippis S, Vita A, De Berardis D. Riva MA, et al. Ther Adv Psychopharmacol. 2021 May 10;11:20451253211012250. doi: 10.1177/20451253211012250. eCollection 2021. Ther Adv Psychopharmacol. 2021. PMID: 34025981 Free PMC article. Review.
We established that lurasidone is suggested at any age, with no gender difference, at all stages of the disease. ...The most frequent reason for switching to other therapies is the need for long-acting formulations, as in patients at risk of very low adherence or suicide. …
We established that lurasidone is suggested at any age, with no gender difference, at all stages of the disease. ...The most frequent …
Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
Citrome L. Citrome L. Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3. Int J Clin Pract. 2011. PMID: 21129135 Review.
Lurasidone is associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, prolactin or the ECG QT interval. ...Principal advantages over some other second-generation antipsychotics are lurasidone's highly favourable …
Lurasidone is associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, prolactin or the ECG …
18 results